Biscayne NeuroTherapeutics
Biscayne Pharmaceuticals discovers and develops novel therapies based on growth hormone-releasing hormone (GHRH) analogs.
Launch date
Employees
Market cap
-
Enterprise valuation
€168m (Public information from Sep 2018)
Miami Florida (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$3.0m | Series B | ||
$185m Valuation: $185m | Acquisition | ||
Total Funding | €2.7m |
Recent News about Biscayne NeuroTherapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.